{"entity":{"id":"nct07043270","kind":"trial","name":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","aka":[],"tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.","summary":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC is a phase 2, interventional study registered as NCT07043270 by Dartmouth-Hitchcock Medical Center, with a registry enrolment figure of 35 participants, started 2025-09-29 and due to reach its primary completion in 2028-07-01. Interventions recorded: Nab-paclitaxel + Gemcitabine; modified FOLFIRINOX (mFOLFIRINOX). Conditions listed: Pancreas Adenocarcinoma. Primary outcome: One-year event-free survival (1y-EFS). Pancreatic eligibility wording from the registry: \"2024 Pancreatic Adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07043270","url":"https://clinicaltrials.gov/study/NCT07043270"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["gemcitabine-nab-paclitaxel","folfirinox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07043270","phase":"2","setting":"24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial","sponsor":"Dartmouth-Hitchcock Medical Center","enrolled":35,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07043270/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}